Cancer researchers at Wake Forest Baptist receive $25 million from National Cancer Institute
WINSTON-SALEM, N.C. – Cancer researchers at Wake Forest Baptist received $25 million from National Cancer Institute, according to a news release.
The six-year award will build on work done through an $18 million grant received by Wake Forest Baptist in 2014.
One of only seven awarded in the country, the grant is designed to focus on extending ongoing clinical research in cardiovascular and neurocognitive complications of cancer treatments and on improving patient well-being during cancer care.
“In contrast to the majority of clinical trials for oncology that try to find new treatments for specific cancers, this program focuses on how different therapies, such as radiation, chemotherapy and immunotherapy, can affect the quality of life for patients and their caregivers dealing with the disease,” said Glenn Lesser, M.D., one of the principal investigators of the grant-funded research and a professor of oncology at Wake Forest Baptist. Co-principal investigator of the grant is Kathryn Weaver, Ph.D., associate professor of public health sciences at Wake Forest Baptist.
For example, doctors know that certain classes of chemotherapy drugs commonly given for breast cancer and lymphomas can cause a permanent decrease in heart function. The Wake Forest Baptist team is looking at ways to protect the heart from damage, as well as clearly defining who may be at risk so that doctors could intervene to prevent or stop the damage.
In addition, the research team is studying the following areas:
• Evaluating how treatments in adolescent and young adult cancer survivors can affect their long-term ability to work;
• Using an internet-based approach to provide rural cancer survivors with counseling for depression;
• Using statins, a common class of drugs, to potentially protect the heart from chemotherapy-induced toxicity;
• Training patient navigators to improve care for African-American patients with early-stage lung cancer, who historically have had poor outcomes;
• Testing and designing an effective smoking-cessation intervention for high-risk patients being screened for lung cancer. A study is underway to compare 12 sites that are doing cessation interventions during the screening process with 12 sites that don’t offer smoking cessation as part of their screenings.
”Extraordinary advances in cancer treatment made in the past decade, including immunotherapy and targeted therapy, are very different from traditional radiation and chemotherapy and often have their own toxicities and complications,” Lesser said. “That is why the NCORP project is so valuable and we are so fortunate to be a part of it.”